Taiho Pharmaceutical Co
Taiho Pharmaceutical Co., Ltd., a prominent player in the pharmaceutical preparation manufacturing industry, is headquartered in Japan. Established in 1963, the company has made significant strides in developing innovative therapies, particularly in oncology and urology. With a strong presence in both domestic and international markets, Taiho operates extensively across Asia, Europe, and North America.
Renowned for its commitment to research and development, Taiho's core products include advanced cancer treatments and supportive care medications, distinguished by their efficacy and safety profiles. The company has achieved notable recognition for its contributions to cancer care, positioning itself as a leader in the pharmaceutical sector. With a focus on improving patient outcomes, Taiho Pharmaceutical continues to drive advancements in healthcare, solidifying its reputation as a trusted name in the industry.
+4 vs industry average
Taiho Pharmaceutical Co’s score of 43 is higher than 55% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Part of the Sustainability team at Taiho Pharmaceutical Co?
- Control how your company's emission story is told
- Respond to customers efficiently
- See who's viewing your profile
Industry Intensity
Pharmaceutical Preparation Manufacturing has below-average carbon intensity
Industry performance
The Pharmaceutical Preparation Manufacturing industry has increased its overall emissions by 132% since 0
Reported emissions
No reported emissions data is available for Taiho Pharmaceutical Co yet.
Taiho Pharmaceutical Co's reported carbon emissions
Taiho Pharmaceutical Co., based in Japan and operating within the Pharmaceutical Preparation Manufacturing industry, has established robust climate commitments. While specific, up-to-date absolute emissions figures are not detailed in the provided data, the company has set ambitious science-based targets (SBTi) for greenhouse gas (GHG) emission reductions.
Taiho Pharmaceutical is committed to a 30% reduction in absolute Scope 1 and Scope 2 GHG emissions by 2030, using 2017 as the base year. Furthermore, the company aims to achieve a 20% reduction in absolute Scope 3 GHG emissions by the same deadline, also from a 2017 baseline. These targets are consistent with keeping global warming to 2°C.
The company's climate initiatives and emissions data are cascaded from its parent organisation, Otsuka Holdings Co., Ltd. specifically for RE100 initiatives and organisational performance data. This demonstrates a commitment to climate action across the corporate family.
Unlock detailed emission data
Access structured emission data, company specific factors and auditable source documents
Taiho Pharmaceutical Co’s Climate Goals (2030 & 2050)
No climate goals have been disclosed for Taiho Pharmaceutical Co yet.
Scope 3 top emissions categories
No scope 3 category breakdown has been disclosed yet.
Climate initiatives

Science Based Targets Initiative

Carbon Disclosure Project
The Climate Pledge
UN Global Compact Climate Champions initiative
RE 100
Inherited from Otsuka Holdings Co., Ltd.Climate Action 100
Emissions comparison with industry peers
View similar organisationsNo peer comparison is available for Taiho Pharmaceutical Co yet.
Usage policy
You’re welcome to quote or reference data from this page, but please include a visible link back to this URL. Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.
Where does DitchCarbondata come from?
Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers
Learn moreCurious to see your top suppliers emissions?
Book a demo for a pilot project